Cargando…

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis

OBJECTIVE: To describe 12-month outcomes for beneficiaries in the 100% Medicare Fee-for-Service (FFS) population with primary and recurrent Clostridioides difficile infection (CDI). DESIGN: A retrospective, descriptive, cohort study of CDI claims from the 100% Medicare FFS population, with a first C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feuerstadt, Paul, Nelson, Winnie W., Teigland, Christie, Dahdal, David N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726521/ https://www.ncbi.nlm.nih.gov/pubmed/36483433 http://dx.doi.org/10.1017/ash.2022.2

Ejemplares similares

Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
por: Nelson, Winnie W, et al.
Publicado: (2021)

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis
por: Amin, Alpesh, et al.
Publicado: (2022)

Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis
por: Feuerstadt, Paul, et al.
Publicado: (2021)

2374. Healthcare Resource Use, Costs, and Recurrences in Patients with Clostridioides difficile Infection: A Real-world Data Analysis
por: Nelson, Winnie, et al.
Publicado: (2019)

2436. Real-world Evidence of Fecal Microbiota Transplant Use and Outcomes in Patients with Clostridioides difficile Infection
por: Nelson, Winnie, et al.
Publicado: (2019)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile
por: Sehgal, Kanika, et al.
Publicado: (2023)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey
por: Lurienne, Lise, et al.
Publicado: (2020)

The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
por: Garris, Cindy, et al.
Publicado: (2015)

The Clinical Burden of Clostridioides difficile in Ontario, Canada
por: Pereira, Jennifer A, et al.
Publicado: (2019)

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
por: Garey, Kevin W, et al.
Publicado: (2023)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

2376. Incidence of Clostridioides difficile Infection Among United States Medicare Advantage Enrollees
por: Heinrich, Kirstin, et al.
Publicado: (2019)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Clostridium difficile Infection
por: Feuerstadt, Paul
Publicado: (2015)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S
por: Dubberke, Erik R, et al.
Publicado: (2021)

Risk Factors Associated with Recurrent Clostridioides difficile Infection
por: Negrut, Nicoleta, et al.
Publicado: (2020)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

Systematic Literature Review on Burden of Clostridioides difficile Infection in India
por: Ghia, Canna J, et al.
Publicado: (2021)

The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings
por: Neuenschwander, James F., et al.
Publicado: (2023)

A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections
por: Malone, Daniel C., et al.
Publicado: (2023)

Epidemiology and Risk Factors of Clostridioides difficile Infections in Germany: A Health Claims Data Analysis
por: Weinke, Thomas, et al.
Publicado: (2023)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
por: Pilon, Dominic, et al.
Publicado: (2019)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection
por: Redding, Laurel E, et al.
Publicado: (2020)

Virulence Factors of Clostridioides (Clostridium) difficile Linked to Recurrent Infections
por: Tijerina-Rodríguez, Laura, et al.
Publicado: (2019)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection
por: Rubio-Mendoza, Daira, et al.
Publicado: (2023)

Pseudomembranes on colostomy in a patient with recurrent Clostridioides difficile infection
por: Ueda, Hideki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3b5p65a2542djvuiikm6t7s2pg